pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Gerresheimer sells Centor and Primary Packaging Plastics units to Apax Partners for €1.5 billion

Jul 30, 2026·read at Endpoints ↗DealNeutral

Gerresheimer announced it is divesting two of its businesses, the Centor unit and the Primary Packaging Plastics (PPP) unit, to private‑equity firm Apax Partners. The transaction is valued at roughly €1.5 billion.

The sale is part of Gerresheimer’s strategy to focus on its core glass packaging and drug‑delivery operations, allowing the company to streamline its portfolio and invest in higher‑growth areas.

The announcement coincided with reports that other companies such as Resilience and Eli Lilly are expanding capacity for injectable pens, highlighting ongoing investment in the injectable market.

Details on the timing of the closing and any impact on employees were not disclosed in the brief report.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity”

read at Endpoints ↗
79 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 31m agoIpsen has 'firepower' for more deals with €2B war chestEndpoints
  • 1h agoAlnylam cuts Amvuttra sales guidance as demand shifts, hurting stockEndpoints
  • 3h agoRelation promises 'transformationally different success rates' in expanded AI pact with GSKEndpoints
  • 5h agoSanofi records €1B+ write-off, ends work on two immunology assetsEndpoints
  • 10h agoJ&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechEndpoints